Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 4/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7141661 | 0.83 | GABRR1 (0.48) | CYP1A2GABRR1ACE2BLMCHRM1 | |
| SCHEMBL18072159 | 0.76 | CYP1A2 (0.50) | CYP1A2GABRR1MAPK1DPP4BLM | |
| SCHEMBL8588431 | 0.72 | BLM (0.48) | CYP1A2GABRR1ACE2BLMCHRM2 | |
| SCHEMBL15865784 | 0.70 | — | — | |
| SCHEMBL29954280 | 0.70 | CYP1A2 (0.45) | CYP1A2MAPK1DPP4BLMCHRM2 | |
| SCHEMBL28440260 | 0.70 | ACE2 (0.57) | CYP1A2GABRR1ACE2BLMZDHHC20 | |
| SCHEMBL5400126 | 0.69 | — | — | |
| SCHEMBL3383959 | 0.67 | BLM (0.52) | CYP1A2GABRR1ACE2BLMLTA4H | |
| SCHEMBL65244 | 0.67 | — | — | |
| SCHEMBL9194314 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022371-A1 | Compositions and methods for detecting and treating tumors containing acidic areas | SUMMERTON JAMES EDWARD (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022371-A1 | Compositions and methods for detecting and treating tumors containing acidic areas | CA1, CA14, CA12 | CYP1A2 4534/4885GABRR1 1494/4885MAPK1 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.